• 01-DEC-2016

  • SOURCE: IBM

IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery

- Collaboration combines IBM Watson’s cognitive computing capabilities with Pfizer’s scientific knowledge to help scientists generate meaningful insights 

IBM Watson Health and Pfizer Inc. today announced a collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer’s research in immuno-oncology, an approach to cancer treatment that uses the body’s immune system to help fight cancer. Pfizer is one of the first organizations worldwide to deploy Watson for Drug Discovery, and the first to customize the cloud-based cognitive tool – tapping in to Watson’s machine learning, natural language processing, and other cognitive reasoning technologies to support the identification of new drug targets, combination therapies for study, and patient selection strategies in immuno-oncology.